CalciMedica, Inc. (CALC) is a clinical-stage biopharmaceutical company developing calcium release-activated calcium (CRAC) channel inhibitors, led by the intravenous candidate Auxora. As a pre-revenue micro-cap, its sell-side coverage is limited and has shifted materially over the past year.
The most current, attributable targets are Guggenheim's $9 Buy rating, initiated in August 2026, and Oppenheimer's $10 Outperform rating, set in March 2026 when the firm lowered its target from $20. Their mean is $9.50, rounded to $10. Separately, H.C. Wainwright downgraded the stock to Hold in January 2026 and no longer carries an active price target. Some data aggregators still display much higher figures — ranging up to roughly $75 — but those reflect stale targets set when shares traded far above current levels and are not representative of present coverage.
Bullish analysts emphasize the clinical promise of the CRAC-channel platform, while the Hold view reflects caution about near-term catalysts and a depressed valuation for a company still far from commercialization. This is not a broad analyst consensus, but a narrow, high-conviction bull camp set against a more cautious observer.
Shares traded near $1.30 in November 2026, within a 52-week range of roughly $1.00 to $36.00 and down about 91% over the prior year. A move to $10 would require upside of approximately 670%, a very large move that effectively assumes a re-rating of the entire business rather than a modest incremental gain.
Because CalciMedica generates no product revenue, the path toward any higher valuation depends almost entirely on clinical execution. Positive Phase 2 data for Auxora in acute pancreatitis (the CARPO trial, announced in late 2024) and progress in the KOURAGE Phase 2 acute kidney injury study are the central value drivers. Financing capacity also matters: with roughly $18.6 million in cash and an ongoing net loss, the company will likely need additional capital to advance its pipeline.
The most durable reference points are the 52-week low near $1.00, which acts as a psychological support level, and the 52-week high near $36.00, which illustrates how far the stock has fallen. The $10 target, while ambitious relative to the current price, would still sit well below that prior high. Because the stock has collapsed so sharply, traditional resistance levels are less meaningful than the broader trend, which remains firmly negative until clinical or financing catalysts emerge.
Analyst price targets typically reflect a roughly 12-month research horizon, though for a clinical-stage company the effective catalyst timeline can stretch further. The targets reviewed here were issued between March and August 2026 and remain subject to revision. Key items to watch include updates from the KOURAGE acute kidney injury trial, any new data or regulatory feedback on Auxora, quarterly cash balances and financing announcements, analyst rating and target revisions, and broader biotech-sector risk appetite, which strongly influences small-cap valuations.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, low-liquidity name like CalciMedica, such tools can help traders spot shifting momentum more efficiently than manual chart review. Traders can use the signals to discover opportunities, monitor existing positions, and identify changing trends across their watchlists as conditions evolve.
The question of whether CalciMedica (CALC) can reach $10 hinges on a dramatic re-rating rather than incremental progress. The target, a rounded mean of two current Buy-rated analyst targets ($9 and $10), implies roughly 670% upside from the latest price near $1.30. Supporting the case are a differentiated CRAC-channel platform and encouraging early clinical data; working against it are the absence of revenue, a constrained cash position, and the inherent failure risk of clinical-stage biotech. With analyst views split between two bullish firms and one downgrade to Hold, and with a narrow target range that sits far above today's price, investors should focus on clinical data, financing decisions, and analyst revisions rather than treating the $10 figure as a near-term expectation. No definitive outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that CALC and OBIO have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CALC and OBIO's prices will move in lockstep.
| Ticker / NAME | Correlation To CALC | 1D Price Change % | ||
|---|---|---|---|---|
| CALC | 100% | -9.57% | ||
| OBIO - CALC | 33% Poorly correlated | +0.53% | ||
| MTNB - CALC | 28% Poorly correlated | -0.81% | ||
| HIND - CALC | 26% Poorly correlated | -3.14% | ||
| ALDX - CALC | 26% Poorly correlated | -1.08% | ||
| LITS - CALC | 26% Poorly correlated | +0.86% | ||
More | ||||